leadf
logo-loader
viewAequus Pharmaceuticals Inc.
(
TSX-V:AQSOTCQB:AQSZF
)

Aequus and partner Medicom Healthcare win Medical Device License for Evolve Daily Intensive product to treat dry eye disease

The formulation contains 350 drops that can be dispensed with gentle squeezing – an important feature for chronic users and many dry eye patients

Aequus Pharmaceuticals Inc. - Aequus Pharmaceuticals Inc wins Medical Device License in Canada for the second of three product submissions made for the Evolve preservative free dry eye product line
Dry eye disease is a common disorder of the tear film that leads to ocular surface damage over time

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) (FRA:AEQ) announced Thursday that it and partner Medicom Healthcare Ltd have been issued a new Medical Device License for the second of three product submissions made for the Evolve preservative-free, dry eye product line. 

In a statement, Aequus said that the license was issued for Evolve Daily Intensive – an advanced formulation of 0.2% Hyaluronate, free of preservatives and phosphates, and made available in a multi-dose bottle for ease of use for all patients. The formulation contains 350 drops that can be dispensed with gentle squeezing – an important feature for chronic users and many dry eye patients. 

“Evolve Daily Intensive is the second lubricating eye drop being offered by Aequus as part of a full line of products made exclusive to Eye Care Professionals,” said Grant Larsen, chief commercial officer at Aequus. 

READ: Aequus and partner Medicom Healthcare win Medical Device License for Evolve Intensive Gel to treat Dry Eye Disease

Aequus CEO Doug Janzen noted that “these Hyaluronate drops, in particular, are seen as the workhorse of the entire line, and are currently the fastest-growing Hyaluronate drops in the UK. The full range is expected to generate $10M a year in Canadian sales at maturity.” 

Aequus said it is advancing launch activities for the newly approved Evolve products, while a third drop in the Evolve range is currently under review with Health Canada.

Dry eye disease (DED) is a common disorder of the tear film that leads to ocular surface damage over time. Previous research has shown DED reduces health and vision-related quality of life and that it carries a considerable economic burden of disease. DED affects about 6.3 million Canadians.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Aequus Pharmaceuticals Inc.

Follow
TSX-V:AQS

Price: 0.125 CAD

Market Cap: $16.58 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Ixico seeing success with a number of contracts awarded covering multiple...

Ixico plc Chief Commercial Officer Lammert Albers joined Steve Darling from Proactive to share news the Clinical Research Organization has awarded the company, on behalf of their biopharmaceutical sponsor,  a 6-figure deal to conduct a Phase II Alzheimer’s disease clinical trial.  Albers...

4 hours, 15 minutes ago

2 min read